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and osteoblastic activity, which in the presence of a low toDose-dependent effects of strontium on bone of chronic renal
normal amount of osteoid (2.7  1.9%) points to the develop-failure rats.
ment of the adynamic type of renal osteodystrophy. Interest-Background. We previously reported on increased bone
ingly, compared to the control-CRF group, histodynamic andstrontium (Sr) levels in dialysis patients with osteomalacia ver-
histologic parameters of the Sr-75 group did not differ signifi-sus those presenting other types of renal osteodystrophy. A
causal role of strontium in the development of osteomalacia cantly and a substantial osteoblastic activity (7.6  4.0%) was
was established in a chronic renal failure (CRF) rat model. seen also. In the Sr-150 group, the various osteoid parameters
Methods. In the present study we investigated whether the were significantly (P  0.05) increased vs. all other groups and
effect of Sr on bone was related to dosage. Four groups of were accompanied by a reduced BFR and mineral apposition
CRF rats were studied: a control group (control-CFR; N  6) rate (MAR) and an increased mineralization lag time (MLT),
not receiving strontium and three groups of animals loaded indicating a mineralization defect and the development of os-
orally with Sr during 18 weeks by adding the element as the teomalacia.
SrCl2 · H20 compound to the drinking water at concentrations Conclusions. Our findings indicate that the role of Sr in the
of 0.03 g/100mL (Sr-30; N  6), 0.075 g/100mL (Sr-75; N  development of bone lesions in renal failure is complex and
6), or 0.15 g/100mL (Sr-150; N  6) respectively. A fifth group that, depending on the dose, the element may act via multiple
consisting of seven animals with intact renal function (control- pathways.
NRF), not receiving Sr served as controls for the effect of CRF
on bone histology.
Results. As compared to the control-NRF and control-CRF
Recently, we assessed the trace element status in 100groups, Sr administration resulted in a dose-dependent increase
in bone and serum Sr levels. No difference in body weight and bone biopsies of dialysis patients presenting the various
biochemical serum and urinary parameters [i.e., calcium (Ca), types of renal osteodystrophy and found bone strontium
phosphorus (P), and creatinine] was noted between the various
(Sr) levels, as well as Sr/calcium (Ca) ratios to be increasedCRF groups. At sacrifice, intact parathyroid hormone (iPTH)
in patients with osteomalacia [1, 2]. Bone Sr and Sr/Calevels of CRF groups were significantly (P  0.05) higher than
the values measured in the control-NRF group indicating the levels were not only elevated compared to individuals
development of hyperparathyroidism secondary to the installa- with a normal bone histology, but also in comparison to
tion of the CRF. This is further supported by the differences in all other types of renal osteodystrophy. Data from abone histomorphometry between the control-CRF and control-
subsequent epidemiologic study revealed that patientsNRF animals, which, respectively, showed an increased amount
of osteoid (mean  SEM 3.4  1.2% vs. 0.37  0.14%, P  coming from particular dialysis centers were at an in-
0.05) in combination with a distinct osteoblastic activity (35  creased risk for accumulation of Sr which mainly origi-
11% vs.2%, P  0.05) and an increased bone formation rate nated from the use of Sr-contaminated acetate-based[(BFR), 677  177 m2/mm2/day vs. 130  50 m2/mm2/day,
concentrates, used to prepare the final dialysis fluid [3].P  0.05]. Bone surface area and erodic perimeter did not
A causal role of Sr in the development of osteomalaciadiffer between the various study groups. In the Sr-30 group,
Sr loading went along with a dramatic reduction of the BFR was established in an experimental study. Here, oral
as indicated by the total absence of double tetracyclin labels administration of the element to a chronic renal failure
(CRF) rat model over a 12-week period by adding the
Key words: osteomalacia, mineralization, osteoblast function, remnant element to the drinking water at a concentration of 0.34
kidney, trace element. g/100mL resulted in the development of distinct osteo-
malacic lesions in contrast to the animals that had notReceived for publication July 25, 2002
Accepted for publication October 15, 2002 received the compound. An additional interesting find-
ing of this study was that rats loaded with aluminum 2003 by the International Society of Nephrology
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(Al) developed adynamic bone, whereas in the group of
animals loaded with both Sr and Al some rats developed
adynamic bone while in others an even more severe
degree of osteomalacia was observed [4].
As suggested in literature, Sr may exert a number of
effects on bone, which may either be beneficial [5–11]
or toxic [12–16]. Such an ambiguous activity on bone has
previously been reported for Al also [17–19]. Sr, when
administered as the ranelate (S12911) compound has
been attributed the ability to act as an uncoupling agent
by increasing the osteoblastic activity without increasing
bone resorption [10, 20]. This and the recent in vitro
finding that the compound may increase cartilage forma-
tion provides the basis for its potential use in the treat-
ment of osteoporosis [10, 20, 21] and osteoarthritis [22].
As previously demonstrated in rats with normal renal
function Sr either directly or indirectly interacts with
bone metabolism in a dose-dependent way. While low
doses of Sr seem to stimulate bone formation [8, 9], high
doses of the element induce a mineralization defect and
increase the amount of osteoid and decrease bone growth
[8, 9, 11]. Indirectly, administration of high Sr doses
leads to hypocalcemia and inhibition of 1-hydroxylase
activity [8, 12, 13, 23, 24], whereas lower doses of the
element induce a small transient decrease in serum Ca
levels and appear not to influence intact parathyroid
hormone (iPTH) or vitamin D levels [8].
Following our previous experimental investigations in Fig. 1. Loading, labeling, and sampling time schedule. Abbreviations
are: Sr, strontium, Al, aluminum, Ca, calcium, P, phosphorus.CRF rats loaded with a relatively high Sr dose [4], the
present study was set up to determine whether the effect
of Sr on bone of CRF rats is dose-related and/or differs
depending on the dose administered. tion were checked and recorded daily. The loading proto-
col was continued over 18 weeks. Rats were sacrificed
the day following the end of the loading protocol. FiveMETHODS
and 2 days before sacrifice, respectively, a demeclocyclinExperimental design
(30 mg/kg) and tetracyclin HCl (30 mg/kg) labeling wasUsing the “remnant kidney” model, CRF was induced
performed. At regular time intervals during the loadingin male Wistar rats at 12 weeks of age. Under sodium
period, blood and urine samples were taken and frozenpentobarbital anesthesia (60 mg/kg) two branches of the
at80C until analysis (Fig. 1). Bone and blood samplesrenal artery of the right kidney were ligated and 2 weeks
were also taken in the control-NRF animals at sacrifice.later the left kidney was removed. Four weeks after
Twenty-four–hour urine samples were collected afternephrectomy rats were divided into four groups: a con-
housing the animals in individual metabolic cages. Bloodtrol group (control-CRF; N  6), which did not receive
was drawn from the tail vein during the loading periodSr and three groups of six animals each, loaded orally
and by cardiac puncture at sacrifice under ether anesthe-with 0.03 g/100 mL (Sr-30), 0.075 g/100mL (Sr-75) or 0.15
sia. Bone and soft tissues were removed at sacrifice andg/100mL (Sr-150) Sr, respectively, added to the drinking
stored at 20C until analysis.water as SrCl2 · H20. A fifth group (control-NRF; N 
The experimental protocol was approved by the local7) consisting of animals with intact renal function not
Ethical Committee for Animal Experiments of the Uni-receiving Sr and having the same age as the CRF rats
versity of Antwerp.at sacrifice (9 months) was included to control for the
effect of CRF on histologic and histodynamic bone pa-
Biochemical and chemical determinationsrameters. The choice of the various Sr doses was based
Creatinine in serum and urine was determined accord-on data of our previous experimental study [4].
ing to the Jaffe´ method. iPTH in serum was measuredRats were pair fed and weighed weekly. Animals had
free access to drink and food. Water and food consump- using the INS-PTH kit (Incstar Corp., Stillwater, MN,
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USA), validated for the analysis of rat serum. Proteinuria (MLT) (days), mean time interval between deposition
and mineralization of any infinitesimal volume of matrix,was determined according to the method of Bradford.
Sr in serum, urine, and bone was analyzed using a Zee- averaged over the entire life span of the osteoid seam;
and bone formation rate (BFR) (m2/mm2/day), the vol-man 3030 atomic absorption spectrometer equipped with
an HGA-600 graphite furnace, an AS-60 autosampler ume of bone formed per unit of time, calculated as the
product of mineral apposition rate and mineralizing sur-and an Anadex DP-9500B silent scribe printer, all from
Perkin-Elmer (Norwalk, CT, USA). To determine Sr face; osteoblast perimeter (%), percentage of osteoid
perimeter covered by cuboidal (active) osteoblasts.in serum, samples were diluted fourfold in a 0.5 mL/L
TritonX-100 to1 mL/L HNO3 solution, whereas urine
Statisticssamples were diluted 1:20 in a 2 mL/L HNO3 solution.
Bone samples were digested with concentrated HNO3 Statistical analysis of the data was done using the
Kruskal-Wallis test followed by the Mann-Whitney testin stoppered polytetrafluoroethylene (PTFE) (Teflon)
tubes. Methods for the determination of Sr have pre- for unpaired comparisons when differences between
groups were noted. Data are expressed as mean SEM.viously been described in detail [25]. Ca and phosphorus
(P) in serum and urine were determined with a Vitros A P value 0.05 was considered to be significant at a
two-tailed level.750 XRC auto-analyzer (Ortho Clinical Diagnostics,
Beersel, Belgium). Ca determinations in urine and bone
were done by flame-atomic absorption spectrometry
RESULTS
(Model 3110; Perkin-Elmer) after diluting the samples
Biochemical and chemical data1:500 in reverse osmosis-water to which 1 g/L lanthanum
was added to avoid phosphate interferences. The daily food and drank consumption did not differ
between the study groups resulting in comparable weights
Bone histology at sacrifice.
As shown in Figure 2A, the comparison of serum creat-At sacrifice, femurs and tibiae were freed of soft tissue.
Of each rat, one bone sample was, after removal of skin inine levels before installation of the CRF (week 0), after
stabilization of the CRF (week 6) and at sacrifice versusand muscle tissue, weighed immediately and stored at
20C until atomic absorption spectrometric bulk analy- the control-NRF group indicates that a moderate CRF
was induced. Urinary protein excretion was significantlysis. The second sample was used for histologic examina-
tion after 24 hours’ fixation in Burkhardt solution and increased in all CRF groups at sacrifice (Fig. 2B). As
shown in Figure 2C, serum iPTH levels increased duringsubsequent transfer to a 70% ethanol solution until fur-
ther processing. Bone samples were then embedded in the loading period in all CRF groups and, at sacrifice,
were significantly (P  0.05) higher than those noted in100% methylmetacrylate. Longitudinal sections (5 m)
of the proximal tibia were cut with a Jung K microtome the control-NRF group indicating the development of a
substantial degree of hyperparathyroidism.and stained according to Goldner for descriptive histol-
ogy. Bone histologic data, as well as dynamic parameters, Serum Ca and P concentrations before loading were
within the normal range in all groups and had not changedare reported using standardized nomenclature and defi-
nitions [26]. The parameters measured include total bone at sacrifice (Fig. 3 A and B). In each group a significant
increase in the urinary Ca excretion was noted at thearea (%), the area of trabecular bone, including both
mineralized bone and osteoid, expressed as a percentage start of Sr loading vs. baseline levels (i.e., before the
installation of CRF), which again dropped at sacrificeof the total tissue area; osteoid area (%), the measured
area of osteoid expressed as a percent of the total bone (Fig. 3C). A similar, be it less pronounced pattern was
noted for the urinary P excretion (Fig. 3D).area), osteoid width (m); the mean width of surface
osteoid seams, calculated by dividing the measured oste- Loading of the animals with different Sr concentra-
tions led to a significant dose-dependent accumulationoid area by the length of the osteoid seams; osteoid perim-
eter (%), trabecular bone perimeter occupied by osteoid of the element in the respective groups. In order to correct
for bone density, we also determined the Ca concentra-as a percent of the total bone perimeter; erodic perimeter
(%), the percentage of trabecular bone perimeter char- tion in bone. The bone Ca content did not differ between
the groups under study. Hence, Sr/Ca ratio’s showed theacterized by the presence of scalloped bone resorptive
lacunae; double-labeled perimeter (%), percentage of same trend as noted for the absolute concentrations (Fig.
4B). As for bone, serum Sr concentrations also signifi-total endosteal surface exhibiting a double fluorescent
tetracyclin label; mineral apposition rate (MAR) (m/ cantly increased in a dose-dependent way (Fig. 4A).
day), the rate by which bone is mineralized, calculated
Histologic dataas the average distance between the midpoints of two
consecutive tetracyclin labels, divided by the time inter- Figure 5 shows Goldner stainings of representative
animals of the various study groups. Compared to theval between the labeling periods; mineralization lag time
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amount of osteoid is low to normal for the degree of renal
failure. No osteoblasts are seen (Fig. 5D) in contrast to
the Sr-75 group where cuboidal, active cells are observed
(Fig. 5E). In the latter group, the amount of osteoid is
comparable to that of the control CRF rats. In the highest
Sr group, however, in the absence of any osteoblastic
activity the amount of osteoid is distinctly increased as
compared to all other groups (Fig. 5F).
Detailed quantitative histomorphometric data per group
are presented in Figure 6. Bone area and erodic perime-
ter did not differ significantly between the various groups.
Comparison of the histomorphometric data of the con-
trol-NRF group with those of the control-CRF group
clearly shows the development of hyperparathyroid bone
disease in the CRF animals as indicated by the significant
(P  0.05) increase of the BFR (677  177 vs. 130  50
m2/mm2/day), MAR (2.36  0.1 vs. 0.86  0.18 m/
day), osteoid area (3.4  1.2 vs. 0.37  0.14%), osteoid
perimeter (17.4 5.31 vs. 3.7 1.49%), and the amount
of active osteoblasts (osteoblast perimeter) (35  11 vs.
2%). The increase in osteoid area and osteoid perime-
ter in the absence of any change in osteoid width in the
control-CRF group further reflects the development of
hyperparathyroidism. In line with this notion and the
increased osteoblastic activity are the significant correla-
tions between MAR and the osteoid area (r  0.97, P 
0.05) and osteoid perimeter (r  0.88, P  0.05).
Comparing the control-CRF animals to those receiv-
ing Sr, a distinct effect could already be observed at the
lowest dose administered. Indeed, in the Sr-30 group
double tetracyclin labels were completely absent in all
rats, while in all but one animal the reduced mineraliza-
tion rate was accompanied by a distinctly lower osteoid
area (0.84 0.29%) and osteoid perimeter (5.4 1.7%),
thus suggesting the development of adynamic bone.
In the Sr-75 group, the osteoid area was comparable
to the mean value noted in the control-CRF animals and
a substantial osteoblastic activity (osteoid perimeter)
(7.6  4%) was observed. There was little variance in
Fig. 2. The various study groups included pre-chronic renal failure osteoid width and osteoid perimeter between rats of(CRF) (), start loading (week 6) ( ), and at sacrifice (week 20) ().
this group. Interestingly, in contrast to the Sr-30 group,(A ) Serum creatinine, (B ) Urinary protein. (C ) Serum PTH levels.
Abbreviations are: C-crf, control-chronic renal failure; C-nrf, control- double tetracyclin labels were seen in all animals of the
intact renal function not receiving Sr; Sr-30, 0.03 g/100 mL Sr; Sr-75, Sr-75 group and the calculated values for double-labeled0.075 g/100mL Sr; Sr-150, 0.15 g/100mL Sr. †P  0.05 vs. week 0; *P 
perimeter, BFR, MAR, and MLT were highly compara-0.05 vs. week 6; #P  0.05 vs. C-nrf.
ble to those of the control-CRF group, indicating Sr to
exert only a minimal effect at this particular dose.
Finally, in all animals of the Sr-150 group double labelscontrol-NRF animals (Fig. 5C) bone histologic findings
were completely absent, which is similar to the Sr-30of rats of the control-CRF group reveal an increased
group. In contrast to this latter group however, the re-amount of osteoid in the presence of active cuboidal
duced tetracyclin incorporation was accompanied by aosteoblasts (Fig. 5 A and B), findings which in view
significantly increased amount of osteoid in all animalsof the increased serum iPTH levels (Fig. 2C) and the
as reflected by the increased osteoid area, osteoid perim-presence of double tetracyclin labels (not shown; see
eter, and osteoid width, pointing to a mineralization de-also quantitative data, Fig. 6) are indicative for the devel-
opment of hyperparathyroidism. In the Sr-30 group the fect and the development of osteomalacia.
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Fig. 3. The various study groups included pre-chronic renal failure (CRF) (), start loading (week 6) ( ), and at sacrifice (week 20) (). (A )
Serum calcium. (B ) Serum phosphorus. (C ) Urinary calcium. (D ) Urinary phosphorus levels. Abbreviations are: C-crf, control-chronic renal
failure; C-nrf, control-intact renal function not receiving Sr; Sr-30, 0.03 g/100 mL Sr; Sr-75, 0.075 g/100mL Sr; Sr-150, 0.15 g/100mL Sr. †P  0.05
vs. week 0; *P  0.05 vs. week 6; #P  0.05 vs. C-nrf.
DISCUSSION The experiments described in this paper were designed
to study whether at lower doses (Sr0.34 g/100mL) (i.e.,As reported previously, bone Sr concentrations as well
the dose used in our first experimental study) Sr was alsoas Sr/Ca ratios are increased in dialysis patients with
able to induce osteomalacia. In addition, these studiesosteomalacia in comparison to those presenting the other
must allow us to find out whether, following observationstypes of renal osteodystrophy [1]. Such an association
in animals with normal renal function, the effects in CRFhas recently been reported by others also [27]. Findings
rats also are dose-related and multiple [8–10]. Comparedof a prospective epidemiologic study revealed that dial-
to our previous experimental study, the use of lower Srysis patients treated in particular dialysis centers were
doses also offers the advantage that they approach theat an increased risk for accumulation of the element,
exposure in the clinical setting of dialysis.which mainly originated from the use of Sr-contaminated
In rats with normal renal function, literature data indi-concentrates to prepare the final dialysis fluid [3]. Data
cated that Sr can exert different effects on bone, whichthus provided evidence for the existence of a so-far un-
appear to be dose-dependent. Whereas low doses of theidentified disease entity within the dialysis population.
element can stimulate bone formation, high doses ofSupport for a causal role of the element in the develop-
the element may induce a mineralization defect [7, 8].ment of this type of renal osteodystrophy was provided
Moreover, due to their versatile effects on bone andby data of an experimental study, in which we were able
ability to uncouple osteoclastic resorption from osteo-to induce a bone disease reflecting the histologic picture
blastic activity [10] and increase cartilage formation, Srof osteomalacia in CRF rats, loaded with Sr during a 12-
compounds have been proposed as potential tools in theweeks period by adding the element to the drinking
treatment of osteoporosis and osteoarthritis [20, 22].water. An interesting additional finding of this study
An ambiguous activity on bone, similar to that of Srwas that rats loaded with Al developed adynamic bone,
has also been shown for Al; an element that within thewhereas in the group of animals loaded with both Sr and
dialysis population is now well recognized to play a roleAl some rats developed adynamic bone, while in others
a more severe osteomalacia was noted [4]. in the development of both osteomalacia and adynamic
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tein excretion reflected the induction of a moderate CFR.
Comparison of the iPTH levels of the control-NFR ani-
mals at sacrifice and CRF groups before the installation
of the CFR to those of the CRF rats at sacrifice revealed
a distinct increase of this parameter. These data thus
indicate the development of a substantial degree of hy-
perparathyroidism and again demonstrate that the “rem-
nant kidney” rat model reflects well the CFR situation
in humans. Serum Ca and P concentrations did not differ
between the various groups. Compared to levels found
before induction of CRF, a hypercalciuria was noted
during the first weeks following the installation of CRF,
which reversed to nearly baseline levels at sacrifice. The
decreased urinary P levels at sacrifice seen in control-
CRF rats as compared to the control-NRF animals might
be due to the severity of the renal insufficiency [30] at this
time point either or not in combination with a possible
inhibitory effect of Sr on the 1-hydroxylase activity [12].
Compared to the rats with normal renal function histo-
morphometric bone analysis in the control-CRF animals
clearly showed an increased amount of osteoid and num-
ber of active osteoblasts in the presence of a distinctly
increased BFR, again indicating the development of hy-
perparathyroidism. Of interest was that these animals
developed a high bone turnover without lowering the
dietary Ca intake and/or increasing the P content of the
diet [30].
In all animals of the highest Sr group (0.15 g/100 mL),
superimposed upon the hyperparathyroidism, an im-
paired mineralization was noted as indicated by a dra-
matically increased mineralization lag time that, in turn,
resulted in a distinctly increased amount of osteoid, thus
Fig. 4. Sr levels measured at sacrifice. (A ) Serum Sr levels. (B) Bone featuring the hallmarks of osteomalacia.
Sr/Ca ratio. A dose-dependent increase was noted. Abbreviations are: In rats exposed to the intermediate Sr dose (0.075C-crf, control-chronic renal failure; C-nrf, control-intact renal function
g/100 mL) bone histomorphometric parameters did notnot receiving Sr; Sr-30, 0.03 g/100 mL Sr; Sr-75, 0.075 g/100mL Sr; Sr-
150, 0.15 g/100mL Sr. †P  0.05 vs. C-crf; #P  0.05 versus C-nrf. substantially differ from those of the control-NRF group.
Hence, at this concentration and in the presence of hy-
perparathyroidism the element appears not to have any
effect on bone. Evidence has been presented in literaturebone disease. Whereas in these patients Al-induced os-
that at comparable doses given to rats with normal renalteomalacia in general only develops in the presence of
function, Sr increases the BFR due to a stimulative effectdistinctly elevated bone Al levels the adynamic lesion
on osteoblastic activity [8, 9], an effect which reasonablymay already occur at normal to slightly elevated levels.
would not be expected in the presence of a an alreadyStudies in rats with normal renal function demonstrated
stimulated bone turnover in the context of CRF.that administration of high doses of the element may
In the lowest Sr group (0.03 g/100 mL) double labelslead to a decrease in bone and matrix formation [28, 29],
were absent indicating a dramatic decrease in BFR inwhile others in both experimental and in vitro studies
all animals. However, in contrast to the rats receivingfound that low doses of Al could stimulate bone forma-
the highest dose (0.15 g/100 mL), this was not accompa-tion [17–19].
nied by an increased amount of osteoid. Rather, bothIn the present study the “remnant kidney” rat model
the osteoid area and osteoid perimeter were decreasedwas used, which is generally accepted to be a suitable
versus the other groups and even did not differ from themethod to induce a moderate, stable CRF in animals.
control-NRF animals. This together with the absence ofLoading of the rats was done over a relatively long period
any osteoblastic activity points to the development of a(18 weeks). This relatively extended loading protocol
so-called adynamic bone.resembles well the biochemical setting of CRF.
The increased serum creatinine levels and urinary pro- Despite the various histologic pictures seen in the dif-
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Fig. 5. Goldner staining of 5 m thick undecalcified trabecular bone sections of rats of the various study groups (magnification 100). (A )
Control-CRF group showed an increased amount of osteoid and increased osteoblastic activity, which in combination with an enhanced bone
formation rate points to the development of hyperparathyroidism, (B ) Detail of (A) shows cuboidal-active osteoblasts covering the osteoid seam
(400) (C ) Control-NRF group. (D ) Sr-30 group shows small amount of osteoid in the absence of osteoblasts, which, in the presence of a reduced
bone formation rate, points to the development of an adynamic bone. (E ) Sr-75 shows slightly increased osteoid in the presence of a distinct
osteoblastic activity. (F ) Sr-150 shows large amount of widened osteoid seams indicative for the presence of osteomalacic lesions.
ferent CRF groups, serum PTH levels did not differ. demonstrated for Al [31]; (2) the development of an
adynamic bone as noted in the Sr-30 group, is mostThis allows us to suggest that (1) Sr, at the serum concen-
trations noted in the present study, does not directly probably due to a direct effect on osteoblast function
rather than being PTH-mediated. This is in line withaffect parathyroid gland function. Such a direct effect
on PTH secretion (not synthesis) has previously been recent in vitro findings in which exposure of primary
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Fig. 6. Histologic data of the various groups. Abbreviations are: C-crf, control-chronic renal failure; C-nrf, control-intact renal function not
receiving Sr; Sr-30, 0.03 g/100 mL Sr; Sr-75, 0.075 g/100mL Sr; Sr-150, 0.15 g/100mL Sr. †P  0.05 vs. C-crf; *P  0.05 vs. Sr-30; ¶P  0.05 vs.
Sr-75, #P  0.05 vs. C-nrf. Data are mean  SEM of six animals except control-NRF (N  7) and Sr-30 (N  5).
osteoblasts to relatively low Sr levels resulted in a re- In order to explain the findings of the present study,
the following hypothesis can be formulated. In the lowestduced osteoblastic activity and impaired cellular differ-
entiation [abstract; Verberckmoes SC et al, J Am Soc Sr group, in the absence of osteoblasts no osteoid is
deposited and hence no mineralization takes place, thusNephrol 12:748, 2001]; and (3) at high levels the osteo-
malacic lesions most likely result from a chemical inter- reflecting the characteristics of adynamic bone. In the
Sr-75 group the suppressive effect on osteoblast functionference of the element with the hydroxyapatite deposi-
tion; an observation corroborating previous in vitro and is no longer observed and mineralization remains intact.
In the Sr-150 group, Sr induces an osteomalacic lesionin vivo findings also [9] [abstract; Verberckmoes SC et
al, J Am Soc Nephrol 12:748, 2001]. as was noted in our previous study also [4].
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